Is anyone able to trade their positions today? TDAmeritrade won't allow trades. My position is just frozen under some sort of corporate action reference.
Can't you read the question Dozer is asking? The question is: Why now? How do you know it is not for a new raise? It is possible I guess that the only reason is the investors were tired of waiting for the right time and demanded it happen right away to make it easier for them to sell out. Nothing makes a whole lot of sense.
Also, you may remember on the last call how the CFO seemed very confident he could be creative to raise money without dilution to the shareholders. He mentioned doing something with Graphon customers or even taking on some debt. So, if the end game here is to incur further dilution at a lower value, this CFO will have NO credibility going forward. It doesn't take any talent or skill to raise funds through the selling of shares at a lower value. I am really hoping our CFO is better than that.
But, you know, Eldad has spent a lot of money on a product he can't sell.
I'm sure there is a good reason. Unfortunately, I can't think of any likely ones that are good for us. If the CFO is doing this to make it easier to sell more shares at a market cap less than 7 million, the entire management should just resign, swear an oath never to be involved in any other new business where they could lose other people's money, and flog themselves weekly in an effort to atone themselves for their hideous incompetence. (But, more likely, they will pat themselves on the back and congratulate themselves for their cleverness and ingenuity in raising funds at a level less than liquidation value.)
However, if they are not doing this to raise funds at a lower market cap than today, but rather as a prelude to an investment (by Citrix?) at a higher level, or there is a partial acquisition in the making, we'll smile, laugh, and sing praises to management. So, which scenario seems more likely to you?
Citrix says 7.8 will come out this quarter. So, any revenue from XenApp hopTo won't be coming until May or June at the earliest, but hopefully in time for Q2 Conference. I hope they haven't abandoned the small enterprise version. If it does work as they implied it would, I think hopTo could make some decent revenue from that version.
If the share price gets any lower, I may be tossing manhole covers in search of a nickel. Yet, I'm not sure the premium will be a matter of just a few nickels in order to make the 1x SO a 1b drug.
But, if the SO 2x nightly becomes generic, won't the SO 1x nightly need to be repriced to compete? How much more will one be willing to pay for SO 1x nightly? Without generics, SO 2x nightly is a 1b drug, but with generics, how much will the SO 1x nightly be worth?
On a positive note of the Mobilis announcement, I don't believe they would have made it if they were not sure they can really get it done. Now it is just a matter of getting it done quickly and properly to meet budget deadlines of the potential customers. Good blurb on hopTo by Gabe Knuth on the Brian Madden blog.
Unfortunately, hopTo still couldn't give an estimate deadline by which the Mobilis project would be complete. Unsettling.
Together with the acquisition, Comtrade signed an ongoing product development and support agreement. I wouldn't be surprised once hopTo is successfully fully integrated with Citrix, the same type of acquisition may take place for the Citrix version of hopTo Work. This may be one reason why the small business version of hopTo Work will be marketed as an entirely new product.
Eliad has already broken that promise. The "exciting deals" did not materialize since, as was explained, the other parties had higher "priorities" to deal with at the moment. So, Eliad again misread the level of interest in the product felt by potential customers. Eliad has made this mistake now numerous times. I just don't know whether this mistake would have been made by other seasoned CEOs or such mistakes are a result of Eliad's relative inexperience.
No, there are many publicly traded companies where the executive team owns and holds on to more than 10% of the shares.
I'm not sure management cares about the price of their stock. It isn't as though they are holding millions of shares. They just issue themselves more shares to sell if the price goes down. They use INFN stock as an ATM for themselves. It takes out all the risk for them. Don't get me wrong, management has done a terrific job with the company but I just don't think they are all that concerned with the price of the shares. A drop in the share price doesn't effect them personally at all. It is the one major thing that has always bothered me about this company.
Might it be the small business hopTo solution? Let's hope so, though I'm not sure what that solution has to do with Citrix. hopTo needs to pick up some revenue while waiting for the larger deals to happen. It is unclear whether the more comprehensive integration with Citrix is ready yet. I think if it were ready, the press release would have made a much bigger splash in that regard.
Defensive? Why, were you attacking me? Oh, you mean that cheap shot at my alleged inexperience with software development. I completely ignored that. I'm not going to waste my time giving you my credentials. I will say in every software project, some type of project schedule is formulated that proposes an estimated time of completion. But, I'm sure you are aware of that.....I guess.
But none of that deters you cuz you are betting on the "compelling nature of HPTO's very own IP". LOL. Talk about inventing stuff, have you looked at the market cap of hopTo lately? It is not as though hopTo's "compelling" IP hasn't been displayed and patents been filed, And, yet, no one seems to want to buy shares, even at this level. Not even management wants to touch them.
Listen, I understand your irrational need to prop up hopTo's management. Believe it or not, I'm rooting for them too. But, I'm trying not to put my head in the sand while I cheer. Maybe you can try to do the same. Go ahead, pull your head out and look around a bit. It is not so bad to see things for the way they are. HopTo still has a chance, but they are going to need some luck to get out of this hole.
I was under the impression management had stated they expected to complete the full integration by the end of the year. But, then, I reviewed the transcript for the 3rd quarter earnings call and saw they never gave any estimated completion date per se, which seems to me very strange and scary. I guess for all the management knows the full integration may not be completed until 2017 sometime, or maybe never. So far, hopTo has not been advertising the Citrix Summit that much, which is a bad sign. Maybe they will start pumping it this last week before the Summit starts. If they don't, it means hopTo has nothing much new to show. Time is running out fast for this management. If they don't do something spectacular this quarter, they need to sell the company to someone who can. Management has had a generous amount of time to show off their business savy but, so far, have failed miserably. If they can't deliver this quarter, they need to step aside and sell the technology to some group that can actually make something out of it.
Your doctor friend sound like an arrogant tool, which fits the profile of many drug peddlers. His total disregard for black boxes explains all the malpractice suits. Does he work for Kaiser? I'll bet other doctors would rather he speak for himself. Anyway, the key takeaway from Svchiro's post was that Sugga has only obtained a 10% market share in Europe after being available on the market for years. I didn't see anything in candyman's response rebutting that statement. Lecturing us on the common term used for the drug doesn't really add to any investment thesis. Maybe he should stick with playing with his chemicals rather than commenting on adult investment matters. Doctors are notorious dimwits when it comes to investing their money. I'll bet professional athletes have a better performance record. At least maybe his comment on the slow ramp up has some value. We'll see.